April 2026
Cannabis
What April 2026's 4 new studies found, synthesized from the papers below. All Cannabis research →
The synthesis
Synthesized from 4 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Cannabis, marijuana, THC, cannabidiol, CBD, then ranked by relevance.
In April 2026, research on cannabis found that cannabis-induced psychosis is characterized by prominent positive symptoms and elevated affective features, with a 36-46% transition rate to schizophrenia spectrum disorders. Regular cannabis use was associated with altered neural and behavioral responses during reward processing, though findings remain inconsistent. Among U.S. cancer survivors aged 50+, lifetime cannabis use prevalence was similar to those without cancer (41.6% vs 42.6%) between 2015-2019, but differences were not significant in 2021-2022. A brief educational video about delta-8 THC increased knowledge and lowered intentions to use among college students with prior but not recent use. Caveats include the need for more consistent findings on neural effects and limited generalizability of the educational intervention.
Confidence in the evidence
Low-Moderate- The systematic review on cannabis-induced psychosis included 36 studies with over 80,000 individuals, providing robust evidence for symptom patterns and transition rates.
- The study on regular cannabis use and reward processing is a single study with inconsistent findings, limiting confidence in the neural and behavioral associations.
- The cancer survivor study is a large nationally representative analysis (n=42,815 and n=21,144) but shows mixed results across time periods, reducing overall confidence.
- The delta-8 THC educational intervention is a small RCT (n=120) with specific population (college students), limiting generalizability.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| A Systematic Review of Clinical Phenomenology, Differential Diagnosis and Prognostic Outcomes of Substance-Induced Psychotic Disorders. 2026 | systematic review | 80000 | Supports | Cannabis-induced psychosis consistently showed prominent positive symptoms, preserved negative domains, elevated affective and anxiety features, with transition rates to schizophrenia spectrum disorders ranging from 36% to 46%. |
| Regular cannabis use is associated with altered neural and behavioural responses during anticipation and feedback of monetary reward and loss 2026 | observational | Mixed | Regular cannabis use was associated with altered neural and behavioural responses during anticipation and feedback of monetary reward and loss, but findings remain inconsistent. | |
| Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site. 2026 | observational | 63959 | Mixed | Between 2015-2019, lifetime cannabis use was similar among cancer survivors (41.6%) and those without cancer (42.6%), but between 2021-2022, overall group differences were not statistically significant. |
| Perceptions of Delta-8 THC and the Impact of a Brief Educational Video Intervention for College Students. 2026 | RCT | 120 | Supports | A brief educational video about delta-8 THC increased knowledge and lowered intentions to use delta-8 THC for students with prior but not recent use. |
Cannabis-induced psychosis consistently showed prominent positive symptoms, preserved negative domains, elevated affective and anxiety features, with transition rates to schizophrenia spectrum disorders ranging from 36% to 46%.
systematic review Sample size: 80000
Regular cannabis use was associated with altered neural and behavioural responses during anticipation and feedback of monetary reward and loss, but findings remain inconsistent.
observational
Between 2015-2019, lifetime cannabis use was similar among cancer survivors (41.6%) and those without cancer (42.6%), but between 2021-2022, overall group differences were not statistically significant.
observational Sample size: 63959
A brief educational video about delta-8 THC increased knowledge and lowered intentions to use delta-8 THC for students with prior but not recent use.
RCT Sample size: 120
Points of agreement
- Cannabis use is associated with distinct clinical and neural alterations, including psychotic symptoms and reward processing changes.
- Educational interventions can increase knowledge and reduce intentions to use cannabinoids in specific populations.
Conflicts
- The study on regular cannabis use and reward processing reports inconsistent findings, conflicting with the expectation of a clear neural signature.
- The cancer survivor study shows no significant difference in cannabis use prevalence between survivors and non-survivors in 2021-2022, contrasting with the 2015-2019 period where use was similar.
Gaps
- Durability of the educational video's effects on delta-8 THC use intentions is not assessed.
- The neural study lacks behavioral performance data linking to neural activity.
- Long-term outcomes of cannabis-induced psychosis beyond transition rates are not fully explored.
- Generalizability of findings to younger cancer survivors or other populations is limited.